Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National...
Informa Markets Rebrands "Electric Vehicle Asia (EVA)" to "MobilityTech Asia - Bangkok," Positioning Thailand as a Regional Hub for Sustainable Mobility Innovation
Informa Markets has announced a significant rebranding initiative: MobilityTech Asia – Bangkok 2025. This transformative event aims to redefine Thailand's automotive industry, elevate it to the global stage, solidify the country's role as a leader...
